Asset Details
Do you wish to reserve the book?
Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4⁺ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4⁺ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients
Do you wish to request the book?
Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4⁺ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4⁺ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients
2011
Overview
Introduction. The impact of highly active antiretroviral therapy (HAART) on CD4+ cell course during treatment with pegylated interferon plus ribavirin (PegIFN-RBV) in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is unknown. Methods. We determined CD4⁺ cell count in 94 HIV-HCV coinfected patients undergoing treatment with pegylated interferon plus RBV at baseline, treatment weeks 4-48 (W4-W48), and months 1, 3, and 6 of follow-up. Of the 94 patients, 70 underwent concomitant HAART (group A) and 24 did not (group B). Results. Group A showed smaller CD4⁺ cell decreases from W24-W48 (P = .027) and greater CD4⁺ cell increases after cessation of pegylated interferon plus ribavirin therapy (P = .002) than group B showed. Conclusions. Concomitant HAART leads to smaller decreases and faster recovery of CD4⁺ cells during and after pegylated interferon plus RBV therapy.
Publisher
Oxford University Press
Subject
/ AIDS
/ Antiretroviral Therapy, Highly Active - methods
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ CD4-Positive T-Lymphocytes - drug effects
/ Female
/ Fundamental and applied biological sciences. Psychology
/ Highly active antiretroviral therapy
/ HIV
/ HIV Infections - complications
/ HIV Infections - drug therapy
/ HIV/AIDS
/ Humans
/ Interferon-alpha - therapeutic use
/ Male
/ Polyethylene Glycols - therapeutic use
/ Viral diseases of the lymphoid tissue and the blood. Aids
/ Virology
/ Viruses
